About Us Contact Us Disclaimer Sitemap
  New Old
HOME TRADING DERIVATIVES PMS MUTUAL FUNDS IPO BONDS RESEARCH MARKET
left «« +1 «« -1 right
 
  Equity Analysis
  Price
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
Weightage
5 Day's Up & Down
Historical Returns
  Volume
  Analysis
  News Analysis
Corporate Action
  Corporate Info
  Other Market
 
Board Meetings  
Sun Pharmaceutical Industries Ltd.
 
BSE Code 524715
ISIN Demat INE044A01036
Book Value(Rs.) 98.39
NSE Code SUNPHARMA
Dividend Yield % 0.66
Market Cap(Rs. in millions) 1001242.48
P/E 112.96
EPS 3.69
Face Value(Rs.) 1  
Source DateBoard Meeting DateDetails
29-Jul-2019 13-Aug-2019 Quarterly Results
10-May-2019 28-May-2019 Dividend inter alia, To consider recommendation of dividend for the year ended March 31 , 2019. & Audited Results
25-Jan-2019 12-Feb-2019 Quarterly Results
22-Oct-2018 13-Nov-2018 SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2018 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, November 13, 2018, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2018. In view of the above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Wednesday, October 31, 2018 to Thursday, November 15, 2018 (both days inclusive). This is for your information and record.
26-Jul-2018 14-Aug-2018 Quarterly Results
10-May-2018 25-May-2018 Dividend & Audited Results
29-Jan-2018 14-Feb-2018 Quarterly Results
30-Oct-2017 14-Nov-2017 1. This is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, November 14, 2017 to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. 2. In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Friday, November 3, 2017 to Thursday, November 16, 2017 (both days inclusive).
26-Jul-2017 11-Aug-2017 Dear Sirs, 1. This is to inform you that a meeting of the Board of Directors of the Company will be held on Friday, August 11, 2017 to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. 2. In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Wednesday, August 2, 2017 to Wednesday, August 16, 2017 (both days inclusive). This is for your information and record.
11-May-2017 26-May-2017 Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 26, 2017, inter alia, to transact the following business: 1. To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. 2. To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. Further, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from May 17, 2017 to May 30, 2017 (both days inclusive). & Dividend & Audited Results
31-Jan-2017 14-Feb-2017 Quarterly Results
25-Oct-2016 10-Nov-2016 Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 10, 2016, inter alia, to transact the following business: 1. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 (Q2). 2. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. & Quarterly Results
02-Aug-2016 12-Aug-2016 Quarterly Results
16-May-2016 30-May-2016 Audited Results & Dividend
28-Jan-2016 12-Feb-2016 Quarterly Results
23-Oct-2015 07-Nov-2015 Quarterly Results
04-Aug-2015 11-Aug-2015 With reference to earlier announcement regarding Q1 results on August 11, 2015, Company has now informed BSE that the Board of Directors of the Company at its meeting scheduled to be held on August 11, 201 5 would also transact the following business: 1. Consideration of the revised audited annual accounts of the Company for the year ended March 31, 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend. 2. Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. & Dividend
28-Jul-2015 11-Aug-2015 With reference to earlier announcement regarding Q1 results on August 11, 2015, Company has now informed BSE that the Board of Directors of the Company at its meeting scheduled to be held on August 11, 201 5 would also transact the following business: 1. Consideration of the revised audited annual accounts of the Company for the year ended March 31, 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend. 2. Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. & Dividend
14-May-2015 29-May-2015 Audited Results
29-Jan-2015 14-Feb-2015 Quarterly Results
Page 1 of 4
Prev || Next
 
Terms & Conditions Copyright ©ATLAS All rights reserved. Designed || Developed & Content Powered By Accord Fintech Pvt.Ltd.

Important Links : SEBI | NSE | BSE | RBI | CDSL | NSDL | Investor Grievance| Policy
SEBI REG. NO. NSE : CASH INB230956935; FO INF230956935; CURRENCY INE230956935 | BSE : CASH INB010956937; FO INF010956937
PMS : INP000000530 | AMFI : ARN0770 | CDSL : IN-DP-CDSL-465-2008